{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:12:06Z","timestamp":1793146326106,"version":"4.5.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pain Res."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chemotherapy-induced peripheral neuropathy (CIPN) is a significant adverse effect of paclitaxel in patients with breast cancer. However, reliable biomarkers for early detection and monitoring of CIPN are lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We investigated neurofilament light chain (NfL) and galectin-3 as candidate biomarkers for CIPN, and performed proteomic analysis to identify novel molecular contributors in two cohorts of patients with breast cancer undergoing paclitaxel therapy. Blood samples were collected longitudinally to measure NfL and galectin-3 levels. Differentially expressed proteins associated with CIPN onset were identified by proteomics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>NfL levels significantly increased in patients with CIPN, from as early as 3 weeks after treatment initiation. NfL levels were markedly higher in patients with vs. without CIPN. There were no changes or between-group differences in galectin-3 levels. Proteomic analysis identified upregulation of alcohol dehydrogenase 4 (ADH4) and downregulation of vesicular overexpressed in cancer prosurvival protein 1 (VOPP1) in CIPN, implicating oxidative stress and disrupted mitochondrial dynamics in the pathogenesis of CIPN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>NfL represents a candidate biomarker for early detection of CIPN, and we identified proteins potentially associated with the development of CIPN. Our findings provide further insights into the pathogenesis of CIPN. Integrating biomarkers and proteomics paves the way for precision medicine to manage chemotherapy-induced toxicities.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpain.2026.1813700","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T05:38:45Z","timestamp":1781588325000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Exploratory identification of candidate biomarkers and molecular contributors to paclitaxel-induced peripheral neuropathy in patients with breast cancer through proteomic analysis"],"prefix":"10.3389","volume":"7","author":[{"given":"Nobuyoshi","family":"Kittaka","sequence":"first","affiliation":[{"name":"Department of Breast Surgery, Osaka Rosai Hospital","place":["Sakai-shi, Osaka, Japan"]},{"name":"Department of Breast and Endocrine Surgery, Osaka International Cancer Institute","place":["Chuo-ku, Osaka, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Tahara","sequence":"additional","affiliation":[{"name":"Department of Cancer Drug Discovery and Development, Research Center, Osaka International Cancer Institute","place":["Chuo-ku, Osaka, Japan"]},{"name":"Center for Clinical Research, Osaka International Cancer Institute","place":["Chuo-ku, Osaka, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Akazawa","sequence":"additional","affiliation":[{"name":"Department of Cancer Drug Discovery and Development, Research Center, Osaka International Cancer Institute","place":["Chuo-ku, Osaka, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Mizote","sequence":"additional","affiliation":[{"name":"Department of Cancer Drug Discovery and Development, Research Center, Osaka International Cancer Institute","place":["Chuo-ku, Osaka, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kitajima","sequence":"additional","affiliation":[{"name":"Translational Research, Ono Pharmaceutical Co., Ltd.","place":["Mishima-gun, Osaka, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Minami","sequence":"additional","affiliation":[{"name":"Drug Discovery Technology, Ono Pharmaceutical Co., Ltd.","place":["Mishima-gun, Osaka, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yurika","family":"Sugano","sequence":"additional","affiliation":[{"name":"Department of Breast and Endocrine Surgery, Osaka International Cancer Institute","place":["Chuo-ku, Osaka, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Nakayama","sequence":"additional","affiliation":[{"name":"Department of Breast and Endocrine Surgery, Osaka International Cancer Institute","place":["Chuo-ku, Osaka, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"102974","DOI":"10.1016\/j.esmoop.2024.102974","article-title":"Pan-Asian adapted ESMO clinical practice guidelines for the diagnosis, treatment and follow-up of patients with early breast cancer","volume":"9","author":"Park","year":"2024","journal-title":"ESMO Open"},{"key":"B3","doi-asserted-by":"publisher","first-page":"101223","DOI":"10.1016\/j.drup.2025.101223","article-title":"Novel insights into taxane pharmacology: an update on drug resistance mechanisms, immunomodulation and drug delivery strategies","volume":"81","author":"Beretta","year":"2025","journal-title":"Drug Resist Updat"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.annonc.2020.07.003","article-title":"Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO\u2013EONS\u2013EANO clinical practice guidelines for diagnosis, prevention, treatment and follow-up","volume":"31","author":"Jordan","year":"2020","journal-title":"Ann Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/j.pain.2014.09.020","article-title":"Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis","volume":"155","author":"Seretny","year":"2014","journal-title":"Pain"},{"key":"B6","doi-asserted-by":"publisher","first-page":"3729","DOI":"10.1007\/s00520-019-04987-8","article-title":"Biological predictors of chemotherapy-induced peripheral neuropathy (CIPN): MASCC neurological complications working group overview","volume":"27","author":"Chan","year":"2019","journal-title":"Support Care Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1200\/JCO.20.01399","article-title":"Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update","volume":"38","author":"Loprinzi","year":"2020","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"174","DOI":"10.3389\/fnmol.2017.00174","article-title":"Pathophysiology of chemotherapy-induced peripheral neuropathy","volume":"10","author":"Starobova","year":"2017","journal-title":"Front Mol Neurosci"},{"key":"B9","doi-asserted-by":"publisher","first-page":"4216","DOI":"10.3390\/cancers15174216","article-title":"Studies to assess the utility of serum neurofilament light chain as a biomarker in chemotherapy-induced peripheral neuropathy","volume":"15","author":"Cavaletti","year":"2023","journal-title":"Cancers"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1158\/0008-5472.CAN-20-2799","article-title":"Pronociceptive roles of Schwann cell-derived galectin-3 in taxane-induced peripheral neuropathy","volume":"81","author":"Koyanagi","year":"2021","journal-title":"Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","first-page":"55","DOI":"10.14889\/jpros.5.2_55","article-title":"Large-scale disease proteomics by aptamer technology","volume":"5","author":"Furuichi","year":"2020","journal-title":"Proteome Lett"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e15004","DOI":"10.1371\/journal.pone.0015004","article-title":"Aptamer-based multiplexed proteomic technology for biomarker discovery","volume":"5","author":"Gold","year":"2010","journal-title":"PLoS One"},{"key":"B13","doi-asserted-by":"publisher","first-page":"15593","DOI":"10.1038\/s41598-022-18716-5","article-title":"Neurofilament light as a predictive biomarker of unresolved chemotherapy-induced peripheral neuropathy in subjects receiving paclitaxel and carboplatin","volume":"12","author":"Burgess","year":"2022","journal-title":"Sci Rep"},{"key":"B14","doi-asserted-by":"publisher","first-page":"636","DOI":"10.2340\/1651-226X.2024.39895","article-title":"Blood biomarkers for neuroaxonal injury and astrocytic activation in chemotherapy-induced peripheral neuropathy","volume":"63","author":"Adra","year":"2023","journal-title":"Acta Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s00415-022-11377-4","article-title":"Serum neurofilament levels correlate with electrodiagnostic evidence of axonal loss in paclitaxel-induced peripheral neurotoxicity","volume":"270","author":"Velasco","year":"2023","journal-title":"J Neurol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1097\/j.pain.0000000000002840","article-title":"Neurofilament light chain as a biomarker of axonal damage in sensory neurons and paclitaxel-induced peripheral neuropathy in patients with ovarian cancer","volume":"164","author":"Mortensen","year":"2023","journal-title":"Pain"},{"key":"B17","doi-asserted-by":"publisher","first-page":"668606","DOI":"10.3389\/fneur.2021.668606","article-title":"A kinetic model for blood biomarker levels after mild traumatic brain injury","volume":"12","author":"Azizi","year":"2021","journal-title":"Front Neurol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e271","DOI":"10.1212\/nxi.0000000000000271","article-title":"Neurofilament light in CSF and serum is a sensitive marker for axonal white matter injury in MS","volume":"3","author":"Bergman","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B19","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.pain.2006.01.037","article-title":"Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: evidence for mitochondrial dysfunction","volume":"122","author":"Flatters","year":"2006","journal-title":"Pain"},{"key":"B20","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.nbd.2015.07.006","article-title":"Paclitaxel inhibits mRNA transport in axons","volume":"82","author":"Bobylev","year":"2015","journal-title":"Neurobiol Dis"},{"key":"B21","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.expneurol.2016.11.015","article-title":"Neurotoxic mechanisms of paclitaxel are local to the distal axon and independent of transport defects","volume":"288","author":"Gornstein","year":"2017","journal-title":"Exp Neurol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/j.1600-065X.2009.00798.x","article-title":"Galectin-3 regulates T-cell functions","volume":"230","author":"Hsu","year":"2009","journal-title":"Immunol Rev"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1017\/s1462399408000719","article-title":"Galectins: structure, function and therapeutic potential","volume":"10","author":"Yang","year":"2008","journal-title":"Expert Rev Mol Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.4103\/1673-5374.391181","article-title":"Emerging role of galectin 3 in neuroinflammation and neurodegeneration","volume":"19","author":"Lozinski","year":"2024","journal-title":"Neural Regen Res"},{"key":"B25","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3390\/toxics9100229","article-title":"Pathomechanisms of paclitaxel-induced peripheral neuropathy","volume":"9","author":"Klein","year":"2021","journal-title":"Toxics"},{"key":"B26","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1136\/jnnp-2018-320106","article-title":"Neurofilament light chain as a biomarker in neurological disorders","volume":"90","author":"Gaetani","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B27","doi-asserted-by":"publisher","first-page":"5947","DOI":"10.1038\/s41598-017-05784-1","article-title":"Taxanes and platinum derivatives impair Schwann cells via distinct mechanisms","volume":"7","author":"Imai","year":"2017","journal-title":"Sci Rep"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e0145816","DOI":"10.1371\/journal.pone.0145816","article-title":"Identifying predictors of taxane-induced peripheral neuropathy using mass spectrometry-based proteomics technology","volume":"10","author":"Chen","year":"2015","journal-title":"PLoS One"},{"key":"B29","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s00520-023-08074-x","article-title":"Evolution of predictive risk factor analysis for chemotherapy-related toxicity","volume":"31","author":"Hertz","year":"2023","journal-title":"Support Care Cancer"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.freeradbiomed.2008.08.030","article-title":"Mechanism of alcohol-induced oxidative stress and neuronal injury","volume":"45","author":"Haorah","year":"2008","journal-title":"Free Radic Biol Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"fcad356","DOI":"10.1093\/braincomms\/fcad356","article-title":"Role of oxidative stress in neurodegenerative disorders: a review of reactive oxygen species and prevention by antioxidants","volume":"6","author":"Houldsworth","year":"2023","journal-title":"Brain Commun"},{"key":"B32","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1124\/jpet.116.237503","article-title":"Oxidative stress and the central nervous system","volume":"360","author":"Salim","year":"2017","journal-title":"J Pharmacol Exp Ther"},{"key":"B33","doi-asserted-by":"publisher","first-page":"C508","DOI":"10.1152\/ajpcell.00076.2004","article-title":"LEDGF regulation of alcohol and aldehyde dehydrogenases in lens epithelial cells: stimulation of retinoic acid production and protection from ethanol toxicity","volume":"287","author":"Fatma","year":"2004","journal-title":"Am J Physiol Cell Physiol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1038\/labinvest.2011.70","article-title":"Loss of VOPP1 overexpression in squamous carcinoma cells induces apoptosis through oxidative cellular injury","volume":"91","author":"Baras","year":"2011","journal-title":"Lab Invest"},{"key":"B35","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/bs.irn.2019.05.001","article-title":"Mitochondrial dysfunction in the pathogenesis of chemotherapy-induced peripheral neuropathy","volume":"145","author":"Trecarichi","year":"2019","journal-title":"Int Rev Neurobiol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"147079","DOI":"10.1016\/j.brainres.2020.147079","article-title":"Resveratrol exerts anti-oxidant and anti-inflammatory actions and prevents oxaliplatin-induced mechanical and thermal allodynia","volume":"1748","author":"Recalde","year":"2020","journal-title":"Brain Res"},{"key":"B37","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.1007\/s11136-022-03154-7","article-title":"Assessing chemotherapy-induced peripheral neuropathy with patient reported outcome measures: a systematic review of measurement properties and considerations for future use","volume":"31","author":"Li","year":"2022","journal-title":"Qual Life Res"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e2424139","DOI":"10.1001\/jamanetworkopen.2024.24139","article-title":"Validity of patient-reported outcome measures in evaluating nerve damage following chemotherapy","volume":"7","author":"Li","year":"2024","journal-title":"JAMA Netw Open"}],"container-title":["Frontiers in Pain Research"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpain.2026.1813700\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T05:38:46Z","timestamp":1781588326000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpain.2026.1813700\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":38,"alternative-id":["10.3389\/fpain.2026.1813700"],"URL":"https:\/\/doi.org\/10.3389\/fpain.2026.1813700","relation":{},"ISSN":["2673-561X"],"issn-type":[{"value":"2673-561X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]},"article-number":"1813700"}}